All In Biotech

Drug Trial Radar · NCT03769194

Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.

Immunogenicity and Safety Study of VLA15, A Multivalent Recombinant OspA (Outer Surface Protein A) Based Vaccine Candidate Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. A Randomized, Controlled, Observer-blind Phase 2 Study.

Last checked: Nov 19, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Dec 17, 2018

Primary completion

Dec 18, 2019

Study completion Oct 2, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study conducted in two study phases: a run-in phase and a main study phase. The study was investigated 3 doses of a multivalent OspA (Outer Surface Protein A) based Lyme vaccine (VLA15) in healthy adults aged 18 to 65 years of age. Study participants received 3 immunizations of the vaccine at a monthly interval. The study assessed the immune response as well as the safety profile of the vaccine.

Conditions

  • Lyme Borreliosis

Interventions

  • VLA15Biological

    a multivalent recombinant Outer surface protein A (OspA) based vaccine candidate

  • PlaceboBiological

    Placebo: PBS (Phosphate Buffered Saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6Time frame: at Day 85 / Month 3

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Clinical Research Consulting, LLC

    Milford, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • United Medical Associates

    Binghamton, New York

  • Regional Clinical Research, Inc.

    Endwell, New York

  • Rochester Clinical Research Inc.

    Rochester, New York

  • Omega Medical Research

    Warwick, Rhode Island

  • Cevac Center for vaccinology

    Ghent, Belgium

  • Berliner Centrum für Reise- und Tropenmedizin (BCRT)

    Berlin, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.